• The Latest and Most Comprehensive Ultra-Large Panel for Human Methylome Research

   

The QuarStar Human MethylCap Panel (NX5001) systematically covers CpG islands, CpG shores, CpG shelves, promoter regions (±2 kb), enhancer regions, differentially methylated regions (DMRs), epigenome-wide association study (EWAS) loci, non-coding RNA regions (lncRNA/miRNA), disease-associated GWAS regions, and highly conserved regions (high phyloP scores).

All target sites were selected based on the latest database annotations (Table 1).

 

 

Table 1. Reference Databases for the QuarStar Human MethylCap Panel

 

The QuarStar Human MethylCap Panel covers 96.65–99.42% of the loci included in multiple mainstream domestic and international large methylation panels and methylation array products (Figure 1-1). In addition, nearly one million high-value CpG sites have been newly incorporated, placing this panel at a leading level in terms of coverage breadth and annotation completeness (Figure 1-2, Figure 1-3).

 

Figure 1. Comprehensive Coverage of the QuarStar Human MethylCap Panel

 

 

 

Figure 1-1. Overlap between the QuarStar Human MethylCap Panel and mainstream methylation array products and large methylation panels (Vendor A, Vendor B, Vendor C, Vendor D).

Figure 1-2. Chromosomal distribution of CpG sites in the QuarStar Human MethylCap Panel.

Figure 1-3. Regional distribution of CpG sites in the QuarStar Human MethylCap Panel (measured in base pairs).

 

• Degenerate Base Probe Design Reduces Cost and Improves Coverage Efficiency

   

Building upon the conventional “four-strand” probe design strategy, Dynegene introduces a unique degenerate base (N/R/S/Y) synthesis approach. This strategy enables the synthesis of multiple combinatorial probes at a single synthesis position, significantly reducing synthesis costs (Figure 2).

 

 

Figure 2. Principles of Methylation Probe Design:

For A, T, and G sites, the reverse complementary sequence is directly used.

For C at non-CpG sites, A is designed in the probe.

For C at CpG sites, which may be either methylated or unmethylated, R (A/G) is incorporated in the probe design.

 

• Methylation-Specific Blocking Reagent: QuarHyb DNA Methyl Enhancer

   

To address the reduced sequence complexity and decreased GC content of methylation libraries, Dynegene has developed a methylation capture enhancer — QuarHyb DNA Methyl Enhancer (NF5010).

Without affecting key performance indicators such as Coverage and Uniformity, this reagent improves blocking efficiency and significantly reduces off-target rates (Figure 3).

 

 

Figure 3. Superior Blocking Performance of QuarHyb DNA Methyl Enhancer

 

• Excellent Capture and Detection Performance

   

The QuarStar Human MethylCap Panel demonstrates outstanding core performance metrics:

Target Ratio: 93.20%, Coverage: 99.02%, Uniformity: 98.47% (Figure 4-1). The panel also shows excellent reproducibility, with a Pearson correlation coefficient of 0.99 (Figure 4-2).

Consistency analysis with WGBS shows a high correlation in methylation levels (Figure 5, R = 0.98), providing a reliable option for both academic research and exploratory clinical studies.

 

 

Figure 4. Excellent Core Performance and Strong Experimental Reproducibility

Figure 4-1. NA24385 library preparation and capture using the QuarStar Human MethylCap Panel and Dynegene methylation-specific hybridization capture reagents.

Figure 4-2. Two replicate experiments using 100 ng NA24385 from library preparation to capture, with sequencing data consistency analysis.

 

Figure 5. High Concordance with WGBS Methylation Levels

 

100ng NA24385 DNA was prepared into libraries and subjected to both WGBS and capture using the Dynegene QuarStar Human MethylCap Panel. Overlapping CpG sites were selected for concordance analysis.